StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2023 it was -$13.49M, down 193.3% from the year before. The highest annual figure on record is $8.12B in fiscal 2021.

Annual net income

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$13.49M-193.3%
FY2022Dec 31, 2022$14.47M-99.8%
FY2021Dec 31, 2021$8.12B+7259.1%
FY2020Dec 31, 2020$110.37M+145.7%
FY2019Dec 31, 2019$44.93M+106.3%
FY2018Dec 31, 2018$21.78M-15.6%
FY2017Dec 31, 2017$25.81M–
FY2016Dec 31, 2016-$596.00K–
FY2015Dec 31, 2015-$1.42M–
FY2014Dec 31, 2014-$1.52M-120.4%
FY2013Dec 31, 2013$7.44M–
FY2011Dec 31, 2011-$844.70K–
FY2010Dec 31, 2010-$8.51M-142.6%
FY2009Dec 31, 2009$19.96M–

More Sinovac Biotech figures

See a number that looks wrong?